The amyloid plaque-busting drug crenezumab for Alzheimer’s disease failed to meet its primary endpoints in a phase II trial, but — as was the case with another similar drug — the drug did show promise in a subgroup with mild symptoms.

Among all patients with mild to moderate Alzheimer’s disease enrolled in the so-called ABBY trial, those assigned to the study drug, a monoclonal antibody called crenezumab, showed a 16.8% reduction in the rate of cognitive decline over 68 weeks compared with a placebo group (P=0.19), reported Jeffrey Cummings, MD, director of the Cleveland Clinic’s Lou Ruvo Center for Brain Health in Las Vegas.

READ FULL ARTICLE Curated publisher From Medical Page Today